[go: up one dir, main page]

AR067077A1 - Preparado solido farmaceutico y metodo de produccion del mismo - Google Patents

Preparado solido farmaceutico y metodo de produccion del mismo

Info

Publication number
AR067077A1
AR067077A1 ARP080102630A ARP080102630A AR067077A1 AR 067077 A1 AR067077 A1 AR 067077A1 AR P080102630 A ARP080102630 A AR P080102630A AR P080102630 A ARP080102630 A AR P080102630A AR 067077 A1 AR067077 A1 AR 067077A1
Authority
AR
Argentina
Prior art keywords
same
production method
solid pharmaceutical
prepared solid
micrometers
Prior art date
Application number
ARP080102630A
Other languages
English (en)
Inventor
Shinsuke Nakagawa
Kai Suzuki
Tadashi Mukai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40070798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR067077A1 publication Critical patent/AR067077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un preparado solido farmacéutico caracterizado porque comprende: (a) 7-cloro-5-hidroxi-1-[2-metil-4-(2-metilbenzoil-amino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepina y/o una sal de la misma; (b) hidroxipropilcelulosa que contiene un grupo hidroxipropoxilo en una cantidad de 50% en peso o mayor; y (c) por lo menos un elemento seleccionado entre el grupo que consiste en carmelosa, carboxi metil almidon sodico, crospovidona e hidroxipropilcelulosa substituida en bajo grado con un diámetro de partícula promedio de 30 a 70 micrometros, y un 90% de diámetro de partícula acumulativo de 100 a 200 micrometros.
ARP080102630A 2007-06-21 2008-06-20 Preparado solido farmaceutico y metodo de produccion del mismo AR067077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007163551 2007-06-21

Publications (1)

Publication Number Publication Date
AR067077A1 true AR067077A1 (es) 2009-09-30

Family

ID=40070798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102630A AR067077A1 (es) 2007-06-21 2008-06-20 Preparado solido farmaceutico y metodo de produccion del mismo

Country Status (24)

Country Link
US (4) US10905694B2 (es)
EP (1) EP2167046B1 (es)
JP (1) JP5289338B2 (es)
KR (1) KR101526625B1 (es)
CN (3) CN103463095A (es)
AR (1) AR067077A1 (es)
AT (1) ATE489944T1 (es)
AU (1) AU2008264445B2 (es)
CA (1) CA2689467A1 (es)
CY (1) CY1111939T1 (es)
DE (1) DE602008003816D1 (es)
DK (1) DK2167046T3 (es)
ES (1) ES2354030T3 (es)
HK (1) HK1201719A1 (es)
HR (1) HRP20100676T1 (es)
IL (1) IL202179A (es)
MX (1) MX2009014193A (es)
MY (1) MY147599A (es)
PL (1) PL2167046T3 (es)
PT (1) PT2167046E (es)
RU (1) RU2466717C2 (es)
SI (1) SI2167046T1 (es)
TW (1) TWI405574B (es)
WO (1) WO2008156217A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102552278A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种提高难溶性药物托伐普坦溶出度的药物组合物
CN102228423B (zh) * 2011-06-29 2013-03-06 重庆市庆余堂制药有限公司 托伐普坦口服固体药物组合物及其制备方法
JP6057628B2 (ja) * 2012-09-06 2017-01-11 クリーンケミカル株式会社 人工透析装置のプライミング方法
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
JP6761695B2 (ja) * 2016-08-16 2020-09-30 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及び固形製剤
JP6838446B2 (ja) * 2017-03-22 2021-03-03 ニプロ株式会社 トルバプタン製剤およびその製造方法
JP7352175B2 (ja) * 2019-12-25 2023-09-28 ニプロ株式会社 トルバプタン製剤
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
JP2024521354A (ja) 2021-06-02 2024-05-31 エスペリオン・セラピューティクス・インコーポレイテッド ベンペド酸とトルバブタンを含む組成物及びそれらを用いた治療方法
EP4321154A1 (en) 2022-08-03 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet of tolvaptan and at least one binder processed with spray granulation
CN120115300B (zh) * 2025-05-13 2025-08-05 洛阳栾川钼业集团股份有限公司 滑石抑制剂及其制备方法及从高滑石辉钼矿的泥精矿中回收钼的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2071511A (en) * 1934-10-01 1937-02-23 Reed & Carnrick Enteric coating
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
JPH09278656A (ja) 1996-02-05 1997-10-28 Sankyo Co Ltd 経口投与用５α−リダクターゼ阻害製剤及びその製造方法
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
JP3746167B2 (ja) * 1998-05-18 2006-02-15 武田薬品工業株式会社 医薬製剤
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
JP2004530676A (ja) * 2001-04-18 2004-10-07 ノストラム・ファーマスーティカルズ・インコーポレイテッド 持続放出性薬学的組成物のための新規コーティング
JP2004026861A (ja) * 2002-06-21 2004-01-29 Shin Etsu Chem Co Ltd 濾過性に優れる水溶性セルロースエーテル及びその選定方法
JP4684545B2 (ja) 2002-09-26 2011-05-18 大日本住友製薬株式会社 溶出性の良好なイソキサゾール誘導体経口製剤
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US8158146B2 (en) * 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride

Also Published As

Publication number Publication date
US10905694B2 (en) 2021-02-02
MX2009014193A (es) 2010-01-28
US20100323006A1 (en) 2010-12-23
RU2010101797A (ru) 2011-07-27
HK1201719A1 (en) 2015-09-11
RU2466717C2 (ru) 2012-11-20
CN103989644A (zh) 2014-08-20
BRPI0813100A2 (pt) 2014-12-23
HRP20100676T1 (hr) 2011-01-31
EP2167046A2 (en) 2010-03-31
KR101526625B1 (ko) 2015-06-05
TW200911270A (en) 2009-03-16
CA2689467A1 (en) 2008-12-24
CN103463095A (zh) 2013-12-25
IL202179A (en) 2012-10-31
SI2167046T1 (sl) 2011-03-31
PL2167046T3 (pl) 2011-05-31
WO2008156217A2 (en) 2008-12-24
MY147599A (en) 2012-12-31
IL202179A0 (en) 2010-06-16
AU2008264445A1 (en) 2008-12-24
AU2008264445B2 (en) 2013-06-27
US20230321113A1 (en) 2023-10-12
PT2167046E (pt) 2011-02-10
US20210069207A1 (en) 2021-03-11
JP5289338B2 (ja) 2013-09-11
ES2354030T3 (es) 2011-03-09
DE602008003816D1 (de) 2011-01-13
ATE489944T1 (de) 2010-12-15
WO2008156217A3 (en) 2009-02-26
KR20100038386A (ko) 2010-04-14
TWI405574B (zh) 2013-08-21
EP2167046B1 (en) 2010-12-01
JP2010530355A (ja) 2010-09-09
CY1111939T1 (el) 2015-11-04
DK2167046T3 (da) 2011-01-31
US20210113582A1 (en) 2021-04-22
CN101686941A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
AR067077A1 (es) Preparado solido farmaceutico y metodo de produccion del mismo
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
BRPI0518093A (pt) dose de nanopartìculas a um paciente, método de intensificação do transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro e dose oral de nanopartìculas que intensifica o transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro
ECSP19046865A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
BRPI0913379B8 (pt) intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PE20100050A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona
PE20150607A1 (es) Composicion farmaceutica que comprende fimasartan e hidroclorotiazida
PE20140926A1 (es) Combinacion anti-retroviral
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
JP2016108327A5 (es)
UY37550A (es) Nueva formulación que comprende un derivado de bencimidazol
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
RU2008147216A (ru) Жидкая лекарственная композиция
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
UY38249A (es) Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
EA202090172A1 (ru) Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib

Legal Events

Date Code Title Description
FC Refusal